Tumor metastasis is a complex process involving the spread of cancer cells from a primary tumor to other parts of the body. The ability of cancer cells to metastasize is a major cause of death in cancer patients.

CD82 and CD9 are two cell surface proteins that have been shown to suppress tumor metastasis in several types of cancer. The exact mechanism by which CD82 and CD9 suppress tumor metastasis is not fully understood, but one possibility is that they inhibit the release of beta-catenin from cancer cells.

Beta-catenin is a protein that plays an important role in the Wnt signaling pathway, which is involved in cell growth, differentiation, and migration. In cancer cells, beta-catenin can promote tumor growth and metastasis.

CD82 and CD9 have been shown to inhibit the release of beta-catenin from cancer cells by binding to beta-catenin and preventing it from being secreted into the extracellular environment. This inhibition of beta-catenin release may contribute to the ability of CD82 and CD9 to suppress tumor metastasis.

Further research is needed to investigate the role of exosomal release of beta-catenin in the suppression of tumor metastasis by CD82 and CD9. This research could lead to the development of new therapies for cancer that target the Wnt signaling pathway.